Browse the evidence

Endurance training adaptations, including visceral fat reduction and cardiac remodeling, are mediated by muscle-secreted IL-6, as blocking IL-6 receptors impairs these specific structural adaptations without affecting peak endurance capacity (VO2peak).

If you are doing endurance training to lose visceral fat or improve heart structure, your body's natural IL-6 response is likely helping you achieve those specific structural goals. However, you do not need to worry about 'blocking' this pathway if you are just trying to improve your overall aerobic fitness (VO2max), as that improvement can still occur even if IL-6 signaling is impaired. Focus on consistent training; the structural benefits are tied to this specific inflammatory-like signaling, but peak capacity is not.

Carbohydrate restriction improves glycemic control and metabolic markers (HbA1c, triglycerides, HDL) in Type 2 Diabetes (T2D), often independent of weight loss, and can lead to 'diabetes reversal' in a subset of patients.

For T2D patients, reducing carbohydrate intake can significantly lower blood sugar and reduce the need for diabetes medications, sometimes even without losing weight. Some patients achieve 'remission' (normal blood sugar without meds). This approach requires working with a doctor to safely reduce medications as blood sugar improves.

Dietary interventions, specifically intermittent fasting (IF) and caloric restriction (CR), improve metabolic profiles (body weight, glucose homeostasis, insulin sensitivity) by inducing epigenetic modifications (DNA methylation and histone modification) in metabolic tissues like adipose, liver, and pancreas.

To improve metabolic health, consider adopting time-restricted feeding (e.g., eating within an 8-10 hour window) or intermittent fasting protocols (like 5:2 or 2:1). These methods can improve insulin sensitivity and reduce body weight, potentially through beneficial changes in how your genes are expressed in fat and liver tissue. Start with a manageable window and consult a healthcare provider, especially if you have diabetes.

Endurance training prioritizes mitochondrial biogenesis over ribosome biogenesis, potentially interfering with resistance training adaptations through AMPK-mTORC1 signaling competition.

If you want to build muscle and improve endurance, be aware that doing both in the same session can blunt some adaptations. To minimize interference, separate your resistance and endurance workouts by at least several hours, or prioritize resistance training first. Focus on your primary goal; if hypertrophy is key, limit high-volume endurance work.

A ketogenic diet causes an upward trend in serum uric acid levels, potentially increasing the risk of gout, requiring increased water intake and possibly sodium bicarbonate to mitigate.

Be aware that starting a ketogenic diet may raise your uric acid levels, which can trigger gout. To mitigate this, drink at least 2 liters of water daily. If you have a history of gout, consult your doctor before starting.

Fasting Mimicking Diets (FMD) and Intermittent Fasting (IF) offer metabolic benefits similar to continuous calorie restriction but with better compliance and potential protective effects against chemotherapy side effects, though long-term weight loss efficacy is modest.

If you struggle with daily calorie counting, try Intermittent Fasting or Fasting Mimicking Diets. They can improve metabolic markers and may protect you during cancer treatment. However, don't expect massive long-term weight loss from IF alone; it's a tool for metabolic health and compliance, not a magic bullet.

Baseline plasma levels of branched-chain amino acids (BCAA) and tyrosine are positively associated with sustained type 2 diabetes remission following weight loss interventions, whereas betaine and choline levels are negatively associated with remission.

If you have type 2 diabetes and are planning weight loss surgery or an intensive lifestyle program, your baseline blood levels of certain amino acids (like BCAA and tyrosine) and choline metabolites might predict how likely you are to reverse your diabetes. Higher levels of BCAA/tyrosine were linked to remission, while higher choline/betaine were linked to non-remission. This suggests metabolic profiling could help tailor treatment, though these specific markers are not yet standard clinical tools.

Flavonoids reduce oxidative stress and inflammation, which are key drivers of obesity and its comorbidities.

Incorporating flavonoid-rich foods can help reduce oxidative stress and inflammation, which are linked to obesity. This supports overall metabolic health but is not a substitute for a healthy diet and exercise.

Dietary carbohydrate intake between 45% and 65% of total calories is not associated with an increased risk of type 2 diabetes, with the lowest risk observed at 50% intake.

You do not need to eliminate carbohydrates to prevent type 2 diabetes. Aim for 45-65% of your daily calories from carbs, with 50% being the sweet spot for lowest risk. Focus on the quality of carbs (e.g., avoiding excessive refined grains like white rice in Asian populations) rather than just quantity.

Dietary carbohydrate intake exceeding 70% of total calories is associated with a significantly higher risk of type 2 diabetes, particularly in Asian populations.

If your diet consists of more than 70% of calories from carbohydrates, you may be at higher risk for type 2 diabetes, especially if you are of Asian descent. Consider reducing carbohydrate intake to the 50-65% range to lower this risk.

Triple agonists (retatrutide, SAR441255) demonstrate superior efficacy in reversing fatty liver disease (MASH) compared to dual agonists and GLP-1 monotherapy.

For those with fatty liver disease (MASH), triple agonists like retatrutide have shown remarkable ability to normalize liver fat in 90% of patients in clinical trials. This makes them a promising treatment option for liver health, beyond just weight loss.

GLP-1 receptor agonists (Liraglutide and Exenatide) significantly improve menstrual frequency and ovulation rates in overweight/obese women with PCOS, primarily through weight loss and insulin resistance reduction rather than direct ovarian stimulation.

For overweight women with PCOS struggling with irregular periods, GLP-1 agonists like Liraglutide or Exenatide (often combined with Metformin) are effective treatments. They improve menstrual regularity and ovulation rates significantly better than Metformin alone. The benefits are largely driven by weight loss and reduced insulin resistance, but may also involve direct hormonal regulation. Consult a doctor for dosing, as injections are required for current FDA-approved versions.

Combining GLP-1 receptor agonists (Liraglutide or Exenatide) with Metformin significantly improves pregnancy rates and endometrial receptivity compared to Metformin monotherapy in women with PCOS undergoing IVF.

If you have PCOS, are overweight, and are struggling with infertility despite trying standard treatments like Clomiphene, ask your doctor about adding Liraglutide to your Metformin regimen before starting IVF. One study showed this combination significantly improved pregnancy rates per embryo transfer compared to Metformin alone. Note that these drugs are not approved for use during pregnancy, so a washout period is required.

Liraglutide treatment is associated with decreased liver fibrosis in patients with type 2 diabetes, as evidenced by lower NAFLD fibrosis score (NFS), FIB-4, and liver stiffness measurement (LSM) after 12 months.

If you have Type 2 Diabetes, ask your doctor about Liraglutide. This medication has been shown to be associated with reduced markers of liver scarring (fibrosis) over a year of use. This is particularly relevant if you are at risk for Non-Alcoholic Fatty Liver Disease (NAFLD), which is common in T2DM. The benefit appears to be linked to its hormonal effects and weight loss.

Once-weekly subcutaneous semaglutide (up to 1.0 mg) in patients with type 2 diabetes produces significant weight loss (-4.69 kg at 6 months, -5.38 kg at 12 months) and improves metabolic parameters, but this weight loss is accompanied by a significant reduction in lean body mass (over 3 kg) that requires mitigation through nutritional education and structured exercise.

If you are using once-weekly semaglutide for Type 2 Diabetes, expect to lose about 5 kg of body weight over 6-12 months, along with improvements in blood sugar and blood pressure. However, this weight loss includes a significant loss of muscle mass (over 3 kg). To counteract this, you must actively engage in resistance exercise and follow a nutrition plan that prioritizes protein, as the medication alone will not preserve your muscle.

A combined nutraceutical product containing Lagerstroemia speciosa, Berberis aristata, Curcuma longa, Alpha-lipoic acid, Chromium picolinate, and Folic acid significantly improves triglycerides, HDL-C, fasting plasma insulin, and HOMA-Index in patients with impaired fasting glucose over an 8-week period.

If you have impaired fasting glucose, a specific combination of plant extracts and micronutrients (Banaba, Berberine, Turmeric, Alpha-lipoic acid, Chromium, Folic acid) taken as two pills daily for 8 weeks, alongside standard dietary and exercise advice, may significantly improve your triglycerides, HDL cholesterol, and insulin resistance markers compared to placebo. This suggests it could be a useful tool for managing metabolic risk in pre-diabetic individuals, though long-term effects are not yet established.

Newer diabetes medications, specifically GLP-1 receptor agonists (like tirzepatide) and SGLT2 inhibitors, facilitate diabetes remission through significant weight loss and glycemic control, though long-term remission data is still emerging.

Newer drugs like tirzepatide and GLP-1 agonists can achieve high remission rates (up to 81%) by combining weight loss with hormonal effects. However, they are expensive, require injections, and long-term remission data is still being gathered. They are a safer alternative to surgery for some, but not a guaranteed cure.

In young adult men, a longer daily eating window is associated with higher insulin resistance (HOMA-IR) and a worse cardiometabolic risk score, while a shorter time from midsleep to first food intake (earlier eating) is associated with better cardiometabolic health.

For young men, how you time your food matters for metabolic health even if it doesn't change your weight. Try to keep your daily eating window shorter (avoid grazing all day) and eat your first meal closer to when you wake up. This pattern is linked to better insulin sensitivity and lower cardiometabolic risk.

Public perception of GLP-1 receptor agonists (GLP-1 RAs) on social media is predominantly neutral-to-positive, driven by reported weight loss efficacy and positive psychological impacts, despite awareness of side effects.

Social media discussions about GLP-1 drugs are largely positive, focusing on weight loss and mental health benefits, though side effects and access issues are common concerns. Patients should be aware that while public sentiment is favorable, individual experiences with side effects and availability vary significantly.

Combining GLP-1 receptor agonists with other Nutrient Stimulated Hormones (NuSH) like glucagon or amylin, or using dual/triple agonists like tirzepatide, may result in less lean mass loss compared to single-agonist GLP-1 treatments.

If you are on semaglutide and worried about muscle loss, ask your doctor if tirzepatide (a dual GLP-1/GIP drug) might be a better option for you, as it appears to spare more muscle. Newer triple-agonist drugs are also in development.

GLP-1 receptor agonists (GLP-1 RA) are associated with significant weight regain after discontinuation, whereas non-GLP-1 related treatments did not show statistically significant regain in this meta-analysis.

If you are on a GLP-1 medication (like semaglutide or liraglutide), stopping it is likely to cause significant weight regain due to the loss of appetite suppression. Other drugs may not show this same statistical pattern of regain in this analysis, but individual responses vary.

Persistent, intrusive, and dysphoric thoughts about food (food noise) are a distinct psychological construct that can be significantly reduced by GLP-1 receptor agonists, leading to improved quality of life and weight management outcomes.

If you experience constant, intrusive, and unpleasant thoughts about food that interfere with your life, this may be 'food noise,' a distinct psychological construct. GLP-1 receptor agonists (like semaglutide) have been shown to significantly reduce this noise, leading to better weight loss outcomes and improved quality of life. This is not a failure of willpower but a treatable condition.

GLP-1 receptor agonists (GLP-1 RAs) are prescribed for Type 2 Diabetes (ADM) and obesity (AOM), with semaglutide being the most commonly prescribed agent overall.

GLP-1 RAs like semaglutide are widely prescribed for diabetes and weight management. If you are considering this treatment, discuss insurance coverage and potential costs with your healthcare provider, as access can be limited by these factors.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a high signal for gastrointestinal adverse events (specifically gastroesophageal reflux disease and dyspepsia) and injection site reactions in real-world post-marketing data, alongside unexpected signals for increased appetite and food craving.

If you are taking tirzepatide, expect gastrointestinal issues like reflux or dyspepsia and injection site reactions (pain, bruising) to be common. Interestingly, while the drug is designed to suppress appetite, some users report increased appetite or food cravings in real-world reports. Monitor your blood glucose if you have diabetes, and report severe abdominal pain (pancreatitis risk) or severe injection site bleeding to your doctor immediately.